title: [Efficacy of compound dihydroartemisinin/piperaquine in treatment of uncomplicated falciparum malaria in Myanmar].
abstract: OBJECTIVE
  To observe the therapeutic efficacy of compound dihydroartemisinin-piperaquine for treatment of uncomplicated falciparum malaria in Myanmar.
  
  
  METHODS
  From 2007 to 2008, patients aged 6 to 60 years with uncomplicated P. falciparum infection and parasite density 500 to 200 000 parasites/microl were enrolled following an informed consent. A three-day course of total 8 tablets compound dihydroartemisinin-piperaquine was administered to an adult (each tablet containing 40 mg of dihydroartemisinin and 320 mg of piperaquine phosphate), dosage for children was based on ages (details in the treatment regimen) . The indices including fever subsiding time, parasite clearance time, asexual parasite clearance time and adverse clinical responses were observed and collected on days 7, 14, 21, and 28 after treatment.
  
  
  RESULTS
  A total of 134 patients completed the treatment. The mean fever subsiding time and mean asexual parasite clearance time were (25.5 +/- 2.8) h and (39.5 +/- 7.8) h respectively. Asexual parasite clearance rate was 100% on day 7. Four cases recrudesced on day 28 and 16 cases had slight adverse clinical responses such as uncomfortable gastrointestinal tract, headache, nausea, vomit and diarrhea, which disappeared as soon as drug withdrawal.
  
  
  CONCLUSIONS
  The compound dihydroartemisinin/piperaquine shows a sound efficacy in treating uncomplicated falciparum malaria
authors.affiliation: Yunnan Instiute of Parasitic Diseases, Yunnan Center of Malaria Research, Institute of Vector and Pathogen Biology of Dali University, Simao 665000, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.forename: Heng-lin
authors.initials: HL
authors.lastname: Yang
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.forename: Chun-Fu
authors.initials: CF
authors.lastname: Li
authors.forename: Ren-hua
authors.initials: RH
authors.lastname: Nie
authors.forename: Heng-ye
authors.initials: HY
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D002052:Myanmar; D011804:Quinolines / Q000627:therapeutic use*; D013607:Tablets; D016896:Treatment Outcome; D055815:Young Adult; D010879:Piperazines
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D011804:Quinolines; D013607:Tablets; C039060:artenimol; C034759:piperaquine; D010879:Piperazines